Douglas Johnson, MD
Internal Medicine · Mechanicsville, VANPI 1134150568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,278 and has fallen 66.0% since, to $435 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$752
- Abbott$439
- Insulet Corporation$329
- Novo Nordisk$212
- Cequr Corporation$208
- Medtronic$172
- plus $2K from 33 others
Across 2 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$38
- GSK$38
What the payments were for
- Food & beverage$4,185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $752 |
| Abbott | 24 | $439 |
| Insulet Corporation | 7 | $329 |
| Novo Nordisk | 12 | $212 |
| Cequr Corporation | 3 | $208 |
| Medtronic(2 entities) | 5 | $172 |
| Stryker | 1 | $169 |
| Dexcom, Inc. | 5 | $160 |
| AstraZeneca | 11 | $159 |
| Sanofi-aventis U.S. LLC | 7 | $150 |
| Amgen(2 entities) | 7 | $122 |
| Amneal Pharmaceuticals LLC | 6 | $109 |
| Xeris Pharmaceuticals, Inc. | 5 | $105 |
| Ascendis Pharma Endocrinology Inc | 1 | $96 |
| Tandem Diabetes Care, Inc. | 4 | $92 |
| Boehringer Ingelheim | 4 | $87 |
| BETA Bionics, Inc. | 3 | $61 |
| Bayer | 3 | $59 |
| Pfizer | 3 | $58 |
| Kyowa Kirin, Inc. | 2 | $51 |
| Merck | 4 | $48 |
| AbbVie | 2 | $47 |
| Johnson & Johnson | 3 | $45 |
| Recordati_rare_diseases_inc. | 2 | $44 |
| Shire North American Group Inc | 3 | $44 |
| Embecta Corp. | 1 | $41 |
| Lifescan, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Sequel Med Tech, LLC | 1 | $29 |
| BD | 1 | $29 |
| IBSA Pharma Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Valeritas, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$173
- AEQUALIS FLEX REVIVE$169
- ZEPBOUND$117
- MINIMED 780G$107
How this compares
$4,185 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 161 | $244,860 |
| TrulicityDulaglutide | 144 | $216,001 |
| JardianceEmpagliflozin | 140 | $160,634 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $87,624 |
| MounjaroTirzepatide | 61 | $78,035 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $72,078 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $63,141 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 40 | $56,839 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 35 | $52,466 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 235 | $52,024 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $46,596 |
| Humalog Kwikpen U-100Insulin Lispro | 85 | $42,334 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $36,969 |
| Novolog FlexpenInsulin Aspart | 95 | $33,312 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $28,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $752 | $316,506276 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $212 | $297,326196 claims |
| Boehringer IngelheimJardiance | $87 | $160,634140 claims |
| MerckJanumet Xr | $48 | $56,83940 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $150 | $39,87468 claims |
| AbbVieSynthroid | $47 | $16,605192 claims |
| Amneal Pharmaceuticals LLCUnithroid | $109 | $13,521158 claims |
| AstraZenecaFarxiga | $159 | $11,12713 claims |
| IBSA Pharma Inc.Tirosint | $25 | $10,90735 claims |
| PfizerLevoxyl | $58 | $6,770148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Mechanicsville
- Kumar AbhishekMechanicsville$1M
- Stanley CzajkowskiMechanicsville$14K
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.